Oxford Nanopore Technologies’ preliminary first-half 2026 revenue came in below management expectations, with weakness attributed to declines in China and the Middle East plus customer timing across regions. The UK nanopore sequencing company expects revenue of about £116.5 million ($156.1 million) for the six months ended June 30, up 10% year over year. The company linked China softness to enhanced export control restrictions and changes in commercial operations, including completion of the PRECISE II contract in Singapore. It also cited geopolitical impact in the Middle East and slower-than-anticipated order timing and contract wins in the Americas. Despite the shortfall versus expectations, Oxford Nanopore maintained full-year 2026 guidance of 21% to 25% constant-currency growth, and highlighted sequencer growth led by its PromethIon platform. Investors will likely focus on whether the geographic headwinds stabilize heading into the second half.